J Cancer 2018; 9(1):100-107. doi:10.7150/jca.21785 This issue


NcRNAs and Cholangiocarcinoma

Zheng Wangyang, Ji Daolin, Xu yi, Li Zhenglong, Huang Lining, Cui Yunfu, Jiang Xingming

Department of Hepatopancreatobiliary Surgery, Second Affiliated Hospital of Harbin Medical University

This is an open access article distributed under the terms of the Creative Commons Attribution (CC BY-NC) license (https://creativecommons.org/licenses/by-nc/4.0/). See http://ivyspring.com/terms for full terms and conditions.
Wangyang Z, Daolin J, yi X, Zhenglong L, Lining H, Yunfu C, Xingming J. NcRNAs and Cholangiocarcinoma. J Cancer 2018; 9(1):100-107. doi:10.7150/jca.21785. Available from https://www.jcancer.org/v09p0100.htm

File import instruction


Cholangiocarcinoma (CCA) is the most common primary biliary malignancy with poor prognosis. Less understanding of its etiology and pathogenesis makes the diagnosis and therapy difficult. Recently, accumulating evidences have demonstrated that deregulated expression of non-coding RNAs (ncRNAs) is closely associated with the etiopathogenesis of CCA. NcRNAs which lack open reading frame are a heterogeneous class of transcribed RNA molecules, including microRNAs, long non-coding RNAs and circular RNAs. Several studies have shown ncRNAs dysregulation is a common central event occurring in CCA and has the potential of being therapy targets. Moreover, ncRNAs can be easily detected in cancer tissues and biofluids, representing valuable tools for diagnosis. In this review, we illustrate the role of ncRNA in the CCA and discuss their potential clinical value.

Keywords: Cholangiocarcinoma, Non-noncoding RNAs, Circular RNAs, Biomarkers, Therapeutic targets.